Addiction
Ancestral Wisdom
Clinical Application of Psychedelics
Clinical Depression
Clinical Research
Health
Healthcare
History
MDMA
Medicinal Use
Mental Health
Novel Therapies
Palliative Care
Psilocybin
Psychedelics
Safety of Psychedelics
Scientific Research
Therapeutic Approaches
Therapy

MDMA-assisted Therapy for PTSD: Its History, Research Data, Therapeutic Approach and Future – 2 CE’S

with Rick Doblin, PhD, Michael Mithoefer, MD, and Annie Mithoefer, BSA

ABOUT THIS PROGRAM

An Evening Event
Monday, March 15, 2021, 7:00 – 9:00 pm EST

This program can be taken individually or as part of the 6-part series, The Psychedelic Renaissance: Past, Present & Future. Recordings of past events in this series are available on demand with registration for the full program. To register for the full series, click here.
Please note CE’s are available only for classes participants attend live, not recorded sessions.

For almost two decades, MAPS (The Multidisciplinary Association for Psychedelic Studies) has been conducting FDA-regulated drug development research into MDMA-assisted therapy for PTSD in the United States, Switzerland, Israel and Canada. We have completed Phase 1 and Phase 2 studies and the first of two Phase 3 studies, with very promising results.

We’re also starting research in five countries in Europe and England for approval by the European Medicines Agency in England, Netherlands, Portugal, Germany, the Czech Republic and Norway. The FDA has awarded Breakthrough Therapy designation to MDMA-assisted Therapy for PTSD.

This evening will address the history of MDMA, our safety and efficacy data, information about mechanisms of action and our therapeutic approach and possible post-approval regulations. We currently anticipate FDA approval around the end of 2022 or early 2023. Approval in Europe would be a year or so later, depending on the availability of funding.

DISCLAIMER: The Open Center, its staff, and presenters do not endorse or encourage the use of psychedelics or any other substances. Substances discussed may be illegal in your country except under very specific circumstances, such as sanctioned medical studies. Any information presented in programs is for curiosity, education and research purposes only.

SCHEDULE & LEARNING OBJECTIVES

Click HERE

Note: This program will be offered online. Sessions of all our online programs will be recorded and shared with registrants after each is completed for 90 days.

CE’S AVAILABLE

MDMA-Assisted Therapy for PTSD
Seminar Code: NYOC-PR-004
Presenter(s): Rick Doblin, Ph.D., Michael Mithoefer, MD and Annie Mithoefer, BSN
Date(s): 3/15/21 | 7:00 – 9:00 pm EST
Metro: Live Interactive Online Webinar

Pricing Information:
Continuing Education Credits (2) $15.00
Please note this fee is for the CE certificate only in addition to the program fee – $40.00
For eligible professions and to purchase the CEs click HERE.
CE certificates will be eligible for download following the course completion at www.ceuregistration.com

The course content is suitable for all levels: Introductory, Beginning, Advanced.

There is no conflict of interest or commercial support for this program.

Refund & Cancellation Policy – click HERE. For questions or concerns, contact registration@opencenter.org.

THIS PROGRAM IS OPEN TO THE PUBLIC. CEs ARE AVAILABLE TO THE FOLLOWING ELIGIBLE PROFESSIONS:

Psychoanalysts
Social Workers
Counselors
Creative Arts Therapists
Educators
Nurses

WHAT YOU’LL NEED FOR THIS COURSE

Prerequisites: N/A
Supplies list for the class: N/A
Zoom Software Requirements: This is an online course that requires Zoom webinar software. Zoom is easy to use. Click HERE to make sure your computer is set-up correctly.